These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25747225)

  • 1. [Present state and future tasks of "Drug Guide for Patients"].
    Isozaki M
    Yakugaku Zasshi; 2015; 135(2):271-5. PubMed ID: 25747225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An examination in comparison Web site with other root on the revised information of drug package insert].
    Okuyama K; Terasawa M; Takahashi T; Yamada Y
    Yakugaku Zasshi; 2005 Aug; 125(8):639-42. PubMed ID: 16079614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What is a medication guide suits patients' needs?].
    Sato T
    Yakugaku Zasshi; 2015; 135(2):297-306. PubMed ID: 25747229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk communication with patients].
    Hirose M
    Yakugaku Zasshi; 2012; 132(5):561-2. PubMed ID: 22687691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing medication errors and increasing patient safety: case studies in clinical pharmacology.
    Benjamin DM
    J Clin Pharmacol; 2003 Jul; 43(7):768-83. PubMed ID: 12856392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Findings from a questionnaire survey on new guidelines for preparing Drug Guide for Patients and a perspective from a pharmaceutical company as the information provider].
    Asada K
    Yakugaku Zasshi; 2015; 135(2):291-5. PubMed ID: 25747228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical risk management in Turkey: the first national overview.
    Aydinkarahaliloglu ND; Aykac E; Kasap Y; Durmus N; Babacanoglu C; Basgut CE; Artiran G; Kerman S
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):344-50. PubMed ID: 23994623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Drives Adoption of National Labels as Global Reference Labels? A Case Study With the JPI.
    Yoshida S; Matsui R; Kikuchi C
    Ther Innov Regul Sci; 2018 Nov; 52(6):724-730. PubMed ID: 29714572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of German package inserts.
    Fuchs J; Hippius M; Schaefer M
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):8-13. PubMed ID: 16425965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacists voice their concern over patient package inserts.
    Koncel JA
    Hospitals; 1978 Jul; 52(14):103-4, 106. PubMed ID: 658918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishing a System for Effectively Explaining Indications for Driving Prohibition Contained in Drug Package Inserts].
    Tanaka M
    Yakugaku Zasshi; 2017; 137(3):337-340. PubMed ID: 28250330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Twenty-year History and Future Challenges in Transparency Enhancement of Review Process for Approval: Focus on Public Release of Review Reports regarding New Drugs and Medical Devices].
    Morimoto K; Kawasaki S; Yoshida Y
    Yakushigaku Zasshi; 2015; 50(1):64-77. PubMed ID: 26427100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excessive medical information increase in package inserts.
    Fuchs J; Werner S; Scheunpflug C; Götze EA; Elstermann K; Scheffel K; Domnowski A; Peter G; Hertzsch C; Hippius M
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):781-90. PubMed ID: 21084033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Patient-oriented package inserts for drugs. Historical overview and current status].
    Van Haecht CH; Vander Stichele R; Bogaert M
    Arch Belg; 1989; 47(5-6):230-55. PubMed ID: 2700065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.